Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06390995 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 28 | TakedaINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06589414 | Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study(DAMeGe) | completed | N/A | 171 | Institut Claudius RegaudOTHER | 1 | Jun 16, 2026 |
| clinicaltrials |
| NCT07307833 | Impact of Immunotherapy on Vestibular Function, The Mayo Clinic Arizona Experience | enrolling by invitation | — | 50 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07649200 | Study of SNH-118110 in Advanced Solid Tumors(SNH-118110) | not yet recruiting | Phase 1 | 240 | ScinnoHub Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650357 | A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) | not yet recruiting | Phase 1 | 140 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650825 | OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02671435 | A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 383 | MedImmune LLCINDUSTRY | 11 | Jun 15, 2026 | clinicaltrials |
| NCT02987166 | HDCRT Plus Pembrolizumab in Advanced Malignancies(UVA-AM-001) | completed | Phase 1 | 21 | James Larner, MDOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05768932 | BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 260 | SillaJen, Inc.INDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06253130 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Eikon TherapeuticsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT07019779 | Study of CM518D1 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07147348 | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 375 | BioNTech SEINDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT07638371 | FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648472 | A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours. | recruiting | Phase 1 | 18 | Joint Biosciences Ltd.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT00991094 | Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy | recruiting | — | 5,000 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04439292 | Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05947474 | ORB-011 In Patients With Advanced Solid Tumors(ORB) | completed | Phase 1 | 55 | Orionis Biosciences IncINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06188208 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | terminated | Phase 1 | 132 | Vividion Therapeutics, Inc.INDUSTRY | 3 | Jun 12, 2026 | clinicaltrials |
| NCT06630416 | Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors | recruiting | Phase 2 | 64 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07284186 | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 155 | Plexium, Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07348653 | A Study of MG2512 Injection in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 116 | Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04266912 | Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04771520 | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06401356 | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | recruiting | Phase 3 | 50 | Novartis PharmaceuticalsINDUSTRY | 5 | Jun 11, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT07163325 | EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors | recruiting | Phase 1 | 48 | Epics TherapeuticsINDUSTRY | 4 | Jun 11, 2026 | clinicaltrials |
| NCT07218003 | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | enrolling by invitation | Phase 1 | 149 | Rondo TherapeuticsINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04243720 | Immune Resistance Interrogation Study(IRIS) | recruiting | — | 100 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 2 | Jun 10, 2026 | clinicaltrials |
| NCT05403177 | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)(MOHCCN-O) | recruiting | — | 500 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05521984 | Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06253195 | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 33 | BeOne MedicinesINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06501040 | Increasing Knowledge and Interest in Cancer Clinical Trials | recruiting | N/A | 384 | Hayley ThompsonOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06788886 | Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases | recruiting | N/A | 147 | Mayo ClinicOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06835569 | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | recruiting | Phase 1 | 448 | Alterome Therapeutics, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06975410 | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Yuhan CorporationINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639047 | An Initial Evaluation of AN8025 in Solid Tumors | recruiting | Phase 1 | 91 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639801 | 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors | not yet recruiting | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT04665388 | LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers(LANDMARC) | recruiting | — | 105 | University Health Network, TorontoOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05530759 | Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal | recruiting | — | 50 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06015932 | Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients | recruiting | N/A | 400 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06314672 | Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial | recruiting | N/A | 208 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07137312 | Ex Vivo Expansion (ACT-X) | recruiting | — | 24 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07534813 | A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors | withdrawn | N/A | 0 | Grit BiotechnologyINDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 16, 2026source: clinicaltrials